Thank you, Ville. So let's talk about the critical aspect of our quarterly release.
So that's the numbers. Obviously a week ago we disclosed some preliminary results, which diminished some of the suspense for this presentation. But I'm really proud and happy to show what we are achieving at the moment. So if we consider the highlights, we have continued the margin recovery in Q2. Actually, this was the best Q2 in the company's listed history.
When it comes to relative margin? We are seeing our adjusted EBITDA increase by 49%; earnings per share by 91. Or if you consider the half-year earnings per share, it has more than doubled. Our leverage stands at 2.5. What does this include regarding IFRS 16? So no matter how you look at this performance, it's solid. You can pick a line in the income statement. You can pick a line in the balance sheet or you can combine those and we are on track. And as we mentioned, it's not only the financial performance, but we also have the NPS customer satisfaction. We have the medical quality pace.
All of these are strong and solid. So we are truly delivering now. Our performance is coming from the Finnish segments and, especially from the healthcare services, which you will see further when we move forward in the slides. Sweden is not visible in the figures, but we have a very clear agenda. We have taken solid steps forward and we are very confident about the progress of our profit improvement program.
So it will be coming in 2025. And all of this merits the guidance update. We will be between 11.5 and 12.5 at the end of this year. So, if we then look a bit at the revenue, basically you could read the headline: Profit Improvement Program - Commercial actions delivering. We are growing 5.5%.
One needs to remember that we had one working day more in the second quarter compared to the previous quarter. That helps slightly with that growth. So the volume adjusted appointment growth or workday adjusted appointment growth is not heavily growing. It's stable, even though it is 1.4% during the quarter in absolute terms, but that supports the growth. Then we have both the customer and service mix working in our favor.
We need to remember also that this is a low demand month or low demand quarter, as is the third quarter, which affects diagnostics and other service sales. So the appointment delivery is more significant and the appointment performance may be better than in Q1 and Q4. And it's worth noting that revenue is increasing in all customer groups and in all services. So we are consistently improving our healthcare services in terms of portfolio businesses. We have the outsourcing decline. We have communicated, you are all aware, and it continues on the anticipated pace.
Staffing continues on the track from Q1. We have been doing some proactive customer selection. We don't want to offer just anything, we want to offer those services where we have solid value, which also converts into profit. And then what comes to dental and massage? We are continuously impacted by the lower consumer purchasing power. The decline has stabilized, but the trend is still very wobbly. It would be difficult to say that it is clearly demonstrating improvement, but it has clearly stabilized during the year and most likely bottomed out during Q1. Then, if we look at Sweden and also consider the story continued, we have ended customer contracts, customer selection, but also a weak demand environment, which is hitting our business model more than in our Finnish business. So all in all, 5.5% growth, very solid growth in our healthcare services, which is the big moat and basically matching improving customer selection and revenue selection, especially in portfolio businesses and Sweden.
Then, if we observe the appetite development adjusted EBITDA from 28.5 to 42.5. Almost 50% improvement. We have healthcare services truly delivering. We are clearly seeing the operational efficiency. And here I want to highlight continuously that it's the low demand season and during that season, the ability to yield margin through all of the services with a sales mix capability is very important. And this is what we have demonstrated now with our profit improvement program that has progressed quicker than anticipated but also delivers very solidly.
So this one, combined with the successful commercial actions and the continued scrutiny on cost, delivers the profit improvement. In our portfolio businesses, we see positive development in staffing and outsourcing. And here, we also see the commercial actions. We have the operational efficiency improvements. But then it's significant to note that we have been fairly solid and effective in adjusting our consumer-driven businesses to the lower demand.
So once the demand starts to pick up, we are lean and prepared to move forward. Also in that respect, and finally in Sweden, the reduction in revenues converts into bottom line. But as stated, the profit improvement program is progressing. Then finally, it's important to note that it's not an adjusted EBITDA topic, but in the adjustment items as mentioned in our profit warning last week, we have a roughly €6 million additional item related to renovation liabilities from a rental contract. This contract is older than a decade.
So, that is truly not for this period. And we don't have similar types of items in our portfolio. So that's good to note. Looking at our total numbers going into the sales mix that has improved in Finland, we continue to face headwinds in Sweden. There’s nothing particularly new that I wouldn’t have already mentioned earlier, but as said, it’s good to note that in healthcare services all client segments are growing.
All services are growing from a revenue perspective and margin creation is really solid. Portfolio business is a bit of a mixed bag, but the revenues are declining in the public sector by choice and in the consumer segments from the market environment. If we then look at H1 as a total, this story continues. Revenues are growing by 4%. So now, no data adjustments are needed. We don't have these types of shows fully comparable year on year; appointments are up by 4%. Uh, a bit less than 1%. It's down. And despite that, we are improving our adjusted EBITDA by 38%. The big contribution comes from healthcare services and portfolio businesses. Uh, still, we are moving towards better and more profitable momentum. And Sweden is in the early stages of the profit improvement program. So it's very natural and understandable, presenting a consistent story with Q1 and Q2. So very consistent, very understandable in my opinion. Then, if we look at cash flow, when we make profit, we generate cash. As simple as that. The clock is ticking. We have a really strong EBITDA and really strong cash flow. We have been fairly conservative on the CapEx side, with -38 million LTM. We continue to be slightly below our own expectations. Maybe, but at the same time, we are doing what is the right thing. We are investing in digital technologies. We are investing in our facilities. And, uh, that's pretty much that. Then, if we look at our leverage, 2.5 continued improvement in the leverage ratio, with interest-bearing liabilities going slightly down. And it's good to note that in Q2, we paid out our dividends. And we have already funded that with operating cash flow. So it's a solid place from which to convert into cash, which is how it always should be. So then we move to the guidance. We expect revenues to grow. There's no change in their adjusted EBITDA, expected to be between 11.5 and 12.5. As you note, the midpoint is at 12%. So, 20 months ago we said we would reach 12% in 2025. Now there is a clear likelihood that we could achieve this already in 2024. Our estimates are based on everything we know at the end of the second quarter. So inflation, consumer demand, employment, and normal morbidity. So still, for Q4, we expect a normal flu season. That's important for our profit generation. We are confident that our performance improvement program continues to deliver and is sustainable. And then we have the same disclaimers as earlier. So all in all, we are very confident in our visibility. We are confident in our first delivery and we are confident in our future delivery. And with these numbers, it's easy to say that 11.5 to 12.5 represents a clear improvement compared to the Q1 release, a clear improvement from the start of the year. And that's where we are with these words.
Any final words will conclude it.